Tryptamine Therapeutics (ASX:TYP) Operating Cash Flow per Share : A$-0.03 (TTM As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Operating Cash Flow per Share?

Tryptamine Therapeutics's operating cash flow per share for the six months ended in Dec. 2023 was A$0.01. Tryptamine Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.03.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 32.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Tryptamine Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

ASX:TYP' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -12.2 Med: 10.05 Max: 32.3
Current: 32.3

During the past 6 years, Tryptamine Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 32.30% per year. The lowest was -12.20% per year. And the median was 10.05% per year.

ASX:TYP's 3-Year OCF Growth Rate is ranked better than
81.46% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs ASX:TYP: 32.30

Tryptamine Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Tryptamine Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Operating Cash Flow per Share Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.09

-0.16

-0.13

-0.12

-0.05

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial						-0.03	-0.09	-0.01	-0.04	0.01

Competitive Comparison of Tryptamine Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Tryptamine Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's Price-to-Operating-Cash-Flow falls into.

Tryptamine Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Tryptamine Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (A: Jun. 2023 )	=	Cash Flow from Operations (A: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (A: Jun. 2023 )
	=	-3.846	/	78.757
	=	-0.05

Tryptamine Therapeutics's Operating Cash Flow per Share for the quarter that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	1.814	/	174.118
	=	0.01

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.03

Tryptamine Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines